Myeloma and the newly diagnosed patient: A focus on treatment and management

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 17, 2002, Pages 5-10

  Rajkumar, S Vincent ^a,b   Kyle, Robert A ^a,b   Gertz, Morie A ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ALGORITHM; ARTICLE; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DRUG MEGADOSE; DYSPNEA; EVIDENCE BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAINTENANCE THERAPY; MYELOMA; PRIORITY JOURNAL; RASH; SMOLDERING MULTIPLE MYELOMA; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0037252631     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34070     Document Type: Article

References (43)

1. Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 336:1657-1664, 1997
2. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
3. Kyle RA: "Benign" monoclonal gammopathy after 20 to 35 years of follow-up. Mayo Clin Proc 68:26-36, 1993
4. Rajkumar SV, Dispenzieri A, Fonseca R, et al: Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 15:1274-1276, 2001
5. Greipp PR, Kyle RA: Staging, kinetics, and prognosis of multiple myeloma, in Wiernik PH, Canellos GP, Dutcher JP, et al (eds): Neoplastic Diseases of the Blood. New York, NY, Churchill Livingstone, 1996, pp 537-559
6. Kyle R, Greipp P: Smoldering multiple myeloma. N Engl J Med 302:1347-1349, 1980
7. Hjorth M, Hellquist L, Holmberg E: Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study: Myeloma Group of Western Sweden. Eur J Haematol 50:95-102, 1993
8. Witzig TE, Kyle RA: Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 87:266-272, 1994
9. Rajkumar SV, Hayman S, Fonseca R, et al: Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (ThaI) as first line therapy for newly diagnosed myeloma (MM). Blood 96:168a, 2000 (abstr A722)
10. Weber DM, Rankin K, Gavino M, et al: Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM). Blood 96:168a, 2000 (abstr)
11. Myeloma Trialists' Collaborative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842, 1998
12. Kovacsovics T, Delaly A: Intensive treatment strategies in myeloma. Semin Hematol 34:49-60, 1997
13. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 330:484-489, 1994
14. Oken MM, Harrington DP, Abramson N, et al: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479. Cancer 79:1561-1567, 1997
15. Harousseau JL, Attal M: The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 34:61-66, 1997
16. Barlogie B, Jagannath S, Epstein J, et al: Biology and therapy of multiple myeloma in 1996. Semin Hematol 34:67-72, 1997
17. Gertz MA, Pineda AA, Chen MG, et al: Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci 309:152-161, 1995
18. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
19. Rajkumar SV, Fonseca R, Lacy MQ, et al: Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 23:1267-1272, 1999
20. Alexanian R, Dimopoulos MA, Delasalle K, et al: Primary dexamethasone treatment of multiple myeloma. Blood 80:887-890, 1992
21. Rajkumar SV, Hayman S, Gertz MA, et al: Combination therapy with thalidomide plus dexamethasone (thal/dex) for newly diagnosed myeloma (MM). Blood 98:2266-2268, 2001
22. Fermand JP, Ravaud P, Chevret S, et al: Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): Results of a prospective randomized trial. Blood 88:685a, 1996 (suppl 11)
23. Facon T, Mary JY, Harousseau JL, et al: Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): Preliminary results of a prospective randomized trial (CIAM) protocol. Blood 88:685a, 1996 (suppl) (abstr)
24. Attal M, Harousseau JL, Facon T: Single versus double transplant in myeloma: A randomized trial of the "Intergroupe Francais Du Myelome" (IFM). VIIIth International Myeloma Workshop Book, Banff, Canada, 2001, p 28
25. Cabo M, Tosi P, Zamagni E, et al: The "Bologna 96" clinical trial of single versus double PBSC transplantation for previously untreated MM: Results of an interim analysis. VIIIth International Myeloma Workshop Book, Banff, Canada, 2001, p 29
26. Segeren CM, Sonneveld P, van der Holt B, et al: Intensive versus double intensive therapy in previously untreated multiple myeloma: A prospective randomized phase III study in 450 patients. VIIIth International Myeloma Workshop Book, Banff, Canada, 2001, p 31
27. Fermand JP, Marolleau JP, Alberti C: Single versus tandem high-dose therapy (HDT) supportedwith autologous blood stem cell (ABSC) transplantation using unselected or CD-34 enriched ABSC: Preliminary results of a two by two design randomized trial in 230 young patients with multiple myeloma. VIIIth International Myeloma Workshop Book, Banff, Canada, 2001, p 147
28. Bensinger WI, Buckner CD, Anasetti C, et al: Allogeneic marrow transplantation for multiple myeloma: An analysis of risk factors on outcome. Blood 88:2787-2793, 1996
29. Cavo M, Bandini G, Benni M, et al: High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone Marrow Transplant 22:27-32, 1998
30. Molina A, Sahebi F, Maloney DG, et al: Non-myelo-ablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM). Blood 96:168a, 2000 (abstr A2063)
31. Maloney DG, Sahebi F, Stockerl-Goldstein KE: Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Presented at the American Society of Hematology 43rd Annual Meeting, December 2001, Orlando, FL (abstr 1822)
32. Moreau P, Misbahi R, Milpied N: Long-term results (10 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Presented at the American Society of Hematology 43rd Annual Meeting, December 2001, Orlando, FL (abstr 2863)
33. Shustik C: Interferon in the treatment of multiple myeloma. Cancer Control 5:226-234, 1998
34. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 322:1430-1434, 1990
35. Browman GP, Bergsagel D, Sicheri D, et al: Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 13:2354-2360, 1995
36. Westin J, Rodjer S, Turesson 1, et al: Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study - Cooperative Study Group. Br J Haematol 89:561-568, 1995
37. Salmon SE, Crowley JJ, Grogan TM, et al: Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 12:2405-2414, 1994
38. Peest D, Deicher H, Coldewey R, et al: A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 2:146-151, 1995
39. Ludwig H, Cohen AM, Polliack A, et al: Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Ann Oncol 6:467-476, 1995
40. Salmon SE, Crowley JJ, Balcerzak SP, et al: Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 16:890-896, 1998
41. Kyle RA: The role of bisphosphonates in multiple myeloma. Ann Intern Med 132:734-736, 2000
42. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996
43. Berenson JR, Lichtenstein A, Porter L, et al: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group. J Clin Oncol 16:593-602, 1998